Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain

Details for Australian Patent Application No. 2004212547 (hide)

Owner Amylin Pharmaceuticals, Inc.

Inventors Coolidge, Thomas R; Ehlers, Mario, R.W.

Agent Freehills

Pub. Number AU-B-2004212547

Parent 774084

Filing date 15 September 2004

Wipo publication date 14 October 2004

Acceptance publication date 20 March 2008

International Classifications

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 31/7004 (2006.01) - Monosaccharides having only carbon, hydrogen and oxygen atoms

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/26 (2006.01) Medicinal preparations containing peptides - Glucagons

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

30 September 2004 Complete Application Filed

14 October 2004 Application Open to Public Inspection

  Published as AU-B-2004212547

20 March 2008 Application Accepted

  Published as AU-B-2004212547

17 July 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004212548-Process for carbonizing wood residues and producing activated carbon

2004212546-FRICTION BAR ASSEMBLY